Addex First Half 2008 Financial Results Monday, July 28

Geneva, Switzerland, 18 July 2008 - Addex Pharmaceuticals Ltd.
(SWX:ADXN) will discuss its financial results for the first half of
2008 and give a pipeline update during a teleconference and webcast
for investors, analysts and the media on Monday, July 28 at 16:00
CET.

Conference Call

Title: Addex First Half 2008 Financial Results Conference Call

Date: 28 July 2008
Time: 16:00 CET
Dial-in numbers: +41 91 610 56 00 (Europe)
+44 207 107 0611 (UK)
+1 866 291 4166 (USA)

The live webcast and slides (and the webcast replay and transcript)
will be available at www.addexpharma.com.

About Us

Addex Pharmaceuticals discovers and develops allosteric modulators
for human health. Allosteric modulators are an emerging class of
orally available small molecule therapeutic agents that we believe
will offer patients better results than classical drugs. Most
marketed drugs bind receptors where the body's own natural molecular
activators (i.e. endogenous ligands) bind, specifically to a key part
of each receptor's anatomy called the "active site". In short, most
drugs must out-compete endogenous ligands for the active site. By
contrast, allosteric modulators are non-competitive because they bind
receptors at a separate site and modify their function even if the
endogenous ligand also is binding the active site. In addition,
because of this, allosteric modulators aren't limited to simply
turning a receptor on or off, the way most drugs are. Instead, they
act more like a dimmer switch, offering control over the degree of
activation or deactivation, while offering the body the ability to
maintain control over initiating receptor activation. Importantly,
the allosteric approach generally affords freedom to operate - even
on well-known, clinically validated targets - because the
intellectual property surrounding allosteric chemistry and the
allosteric sites on receptors is most often un-exploited.

ADX10059, our most advanced product, is a negative allosteric
modulator (NAM) of metabotropic glutamate receptor 5 (mGluR5). It has
demonstrated clinically and statistically significant efficacy in
separate Phase IIa clinical trials in gastroesophageal reflux disease
(GERD) patients and migraine headache patients.

Our products and the Addex allosteric modulation discovery and
development platform have been additionally validated through
collaborations with Merck & Co., Inc. and Johnson & Johnson as well
as investments by Roche Ventures and SR One, the venture investment
arm of GlaxoSmithKline.

Contact

Chris Maggos
Head of Investor Relations & Communications
Addex
Pharmaceuticals
+41 22 884 15 11 Direct
chris.maggos@addexpharma.com

Disclaimer
The foregoing release contains forward-looking statements that can be
identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would",
"could", or similar expressions, or by express or implied discussions
regarding Addex Pharmaceuticals Ltd, its business, the potential
approval of its products by regulatory authorities, or regarding
potential future revenues from such products. Such forward-looking
statements reflect the current views of Addex Pharmaceuticals Ltd
regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results with
allosteric modulators of mGluR4, mGluR2 or mGluR5 to be materially
different from any future results, performance or achievements
expressed or implied by such statements. There can be no guarantee
that allosteric modulators of mGluR4, mGluR2 or mGluR5 will be
approved for sale in any market or by any regulatory authority. Nor
can there be any guarantee that allosteric modulators of mGluR4,
mGluR2 or mGluR5 will achieve any particular levels of revenue (if
any) in the future. In particular, management's expectations
regarding allosteric modulators of mGluR4, mGluR2 or mGluR5 could be
affected by, among other things, unexpected actions by our partners,
unexpected regulatory actions or delays or government regulation
generally; unexpected clinical trial results, including unexpected
new clinical data and unexpected additional analysis of existing
clinical data; competition in general; government, industry and
general public pricing pressures; the company's ability to obtain or
maintain patent or other proprietary intellectual property
protection. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual
results may vary materially from those anticipated, believed,
estimated or expected. Addex Pharmaceuticals is providing the
information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.
Copyright © Hugin AS 2008. All rights reserved.